Head to Head Study: Insulin vs. GLP-1 Receptor Agonists

Over-the-Counter Insulin: What to Know Before You Buy

Novo Nordisk erhält FDA-Zulassung für wöchentliches Basalinsulin Awiqli vor US-Markteinführung 2026

Novo Nordisk redépose Awiqli® auprès de la FDA, potentiellement premier traitement d'insuline icodec hebdomadaire pour adultes atteints de diabète de type 2

Novo Nordisk redépose Awiqli® auprès de la FDA, pouvant devenir la première insuline basale hebdomadaire pour adultes atteints de diabète de type 2

Potential microdosing GLP-1 *side effects* we’re NOT complaining about 👀👇 The science? Better blood sugar control, improved insulin sensitivity, and lower insulin levels. What that means to you? - Calmer appetite cues (no more all-or-nothing hunger) - Less “food noise”, meaning fewer constant thoughts about eating - More stable energy throughout the day - Fewer fatigue crashes - Reduced inflammation bloating - Indirect hormone support - Heart health benefits beyond the scale: Better blood pres